Article 1:
Preemptive-TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study
Hepatology, VOL . 69, NO. 1, 2019
DOI: https://doi.org/10.1002/hep.30182
PDF: Article
Summary: This is a multi-center observational study in patients with cirrhosis who are admitted with acute variceal bleeding with the main aim of evaluating whether the use of pre-emptive TIPS improves the outcome of these patients (mortality, treatment failure, rebleeding risk).
Presenter: April Wall
_______________________________________________________________________________
Article 2:
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection
N Engl J Med 2022; 386:220-229
DOI: https://doi.org10.1056/NEJMoa2106516
PDF: Article
Summary: Current therapies for recurrent Clostridioides difficile infection do not address the disrupted microbiome, which supports C. difficile spore germination into toxin producing bacteria. SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores for the treatment of recurrent C. difficile infection. We conducted a phase 3, double-blind, randomized, placebo-controlled trial in which patients who had had three or more episodes of C. difficile infection (inclusive of the qualifying acute episode) received SER-109 or placebo (four capsules
daily for 3 days) after standard-of-care antibiotic treatment. In patients with symptom resolution of C. difficile infection after treatment with standard-of-care antibiotics, oral administration of SER-109 was superior to placebo in reducing the risk of recurrent infection.
Presenter: Kara Wegermann
